Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Craif raises ¥5.3B Series D funding, totaling about $33 million, to advance US pancreatic cancer research and product launch.

PRIVATEAug 18, 2026•about 4 hours ago

Amount Raised

¥5.3 Billion

Round Type

Series D

BunkyoBiotechnology

Description

Japanese biotech startup Craif has raised roughly ¥5.3 billion (about $33 million) in a Series D round. The funding will support US R&D towards an insurance-reimbursed product launch and regulatory approval for a pancreatic cancer software in Japan. Craif aims to enhance early cancer detection using its innovative urine-based method. The round included investors from Singapore, the US, and Japan.

Company Information

Company

Craif

Location

5F Hongo ITP Office , 2-25-7 Yushima

Bunkyo, Tokyo, Japan

About

Craif is a molecular diagnostics company leveraging miRNA and machine learning for early cancer detection. Our proprietary platform, launched in Japan in 2022, powers the miSignal test, which screens for seven cancers (pancreatic, ovarian, esophageal, lung, breast, colorectal, and gastric) and has seen over 400% YoY revenue growth. In parallel with the commercialization of miSignal, we have started the clinical trial for the IVD test - pancreatic cancer diagnostic test for high risk population (e.g. diabetes, pancreatitis, etc.). This is a test seeking FDA/PMDA approval and planned to be reimbursed by insurance companies in the U.S. and reimbursed by the National Healthcare System in Japan. The clinical trial in Japan started in April 2024 and is planned to obtain approval in 2027H1.

Don't miss Craif's next move

Get an email the moment Craif raises, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
1 contact
Verified contactsMika M., Director
Predictive Intelligence
Strategic

ML-powered predictions for Craif's next move

Learn about Strategic plan

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.